Summary

The veterinary vaccines market is projected to reach USD 18.46 billion by 2031, from USD 13.02 billion in 2026, at a CAGR of 7.2%.” during the forecast period. The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion. “The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period.” Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market. “The intramuscular segment to capture the largest market share of veterinary vaccines market.” Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming. “Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region.” The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3– 25% • By Designation: Directors–25%, Managers–50% and Others–25% • By Region: North America–35%, Europe–30%, Asia Pacific–15% and RoW–20% The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogénesis Bagó (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands). Research Coverage This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence. This report provides insights on the following pointers:  Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)  Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market  Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market  Market Development: Comprehensive information on lucrative emerging regions  Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market  Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 36
1.3.1 MARKETS COVERED & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 38
1.5 LIMITATIONS 38
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 39
2 EXECUTIVE SUMMARY 40
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 40
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 41
2.3 DISRUPTIVE TRENDS IN VETERINARY VACCINES MARKET 42
2.4 HIGH-GROWTH SEGMENTS 43
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 44
3 PREMIUM INSIGHTS 45
3.1 VETERINARY VACCINES MARKET OVERVIEW 45
3.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY AND END USER 46
3.3 GEOGRAPHIC SNAPSHOT OF VETERINARY VACCINES MARKET 47
4 MARKET OVERVIEW 48
4.1 INTRODUCTION 48
4.2 MARKET DYNAMICS 48
4.2.1 DRIVERS 49
4.2.1.1 Increase in companion animal population and pet ownership 49
4.2.1.2 Increasing incidence of infectious and zoonotic diseases 51
4.2.1.3 Favorable initiatives by government agencies and animal health organizations 51
4.2.1.4 Growing demand for animal-derived food products 52
4.2.1.5 Increasing pet insurance penetration and animal health expenditure 54
4.2.2 RESTRAINTS 55
4.2.2.1 High cost of veterinary vaccine development, manufacturing, and cold-chain distribution 55
4.2.3 OPPORTUNITIES 56
4.2.3.1 Advancements in vaccine technologies and strategic collaborations 56
4.2.3.2 Untapped opportunities in emerging livestock and companion animal markets 57
4.2.4 CHALLENGES 57
4.2.4.1 Limited awareness, training gaps, and shortage of veterinary professionals in low-income countries 57
4.2.4.2 Stringent regulatory pathways and complex approval frameworks 58
4.3 UNMET NEEDS & WHITE SPACES 58
4.3.1 UNMET NEEDS IN VETERINARY VACCINES MARKET 58
4.3.2 WHITE SPACE OPPORTUNITIES 59
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.4.1 INTERCONNECTED MARKETS 60
4.4.2 CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 61
4.5.1 STRATEGIC MOVES IN VETERINARY VACCINES MARKET 61
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 THREAT OF NEW ENTRANTS 64
5.1.2 THREAT OF SUBSTITUTES 64
5.1.3 BARGAINING POWER OF SUPPLIERS 65
5.1.4 BARGAINING POWER OF BUYERS 65
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC INDICATORS 66
5.2.1 INTRODUCTION 66
5.2.2 GDP TRENDS & FORECAST 66
5.2.3 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY 67
5.2.4 TRENDS IN GLOBAL VETERINARY BIOLOGICS INDUSTRY 67
5.3 SUPPLY CHAIN ANALYSIS 67
5.4 VALUE CHAIN ANALYSIS 69
5.5 ECOSYSTEM ANALYSIS 70
5.5.1 MANUFACTURERS 71
5.5.2 END USERS 72
5.5.3 REGULATORY BODIES 72
5.6 PRICING ANALYSIS 73
5.6.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025 74
5.6.2 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025 75
5.6.3 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023–2025 76
5.6.4 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY REGION, 2023–2025 77
5.7 TRADE ANALYSIS 77
5.7.1 IMPORT DATA (HS CODE 3002) 78
5.7.2 EXPORT DATA FOR (HS CODE 3002) 78
5.8 REIMBURSEMENT SCENARIO 79
5.9 KEY CONFERENCES & EVENTS, 2026–2027 79
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.11 INVESTMENT & FUNDING SCENARIO 81
5.12 CASE STUDY ANALYSIS 82
5.13 IMPACT OF 2025 US TARIFFS ON VETERINARY VACCINES MARKET 83
5.13.1 INTRODUCTION 83
5.13.2 KEY TARIFF RATES 84
5.13.3 PRICE IMPACT ANALYSIS 85
5.13.4 IMPACT ON COUNTRY/REGION 86
5.13.5 IMPACT ON END-USE SEGMENTS 87
5.13.5.1 Veterinary Hospitals 87
5.13.5.2 Veterinary Clinics 88
5.13.5.3 Other End Users (Veterinary Research Organizations, Government Vaccination Centers) 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 TECHNOLOGY ANALYSIS 89
6.1.1 KEY EMERGING TECHNOLOGIES 89
6.1.1.1 Recombinant DNA technology 89
6.1.1.2 mRNA-based vaccines 89
6.1.2 COMPLEMENTARY TECHNOLOGIES 90
6.1.2.1 Vaccine adjuvant technology 90
6.1.2.2 Needle-free & microneedle technology 90
6.1.3 ADJACENT TECHNOLOGIES 90
6.1.3.1 Genome editing technology 90
6.2 TECHNOLOGY/PRODUCT ROADMAP 91
6.2.1 NEAR TERM (2025–2027) 91
6.2.2 MID TERM (2028–2030) 91
6.2.3 LONG TERM (2030+) 92
6.3 PATENT ANALYSIS 92
6.3.1 JURISDICTION & TOP APPLICANT ANALYSIS 92
6.4 FUTURE APPLICATIONS 96
6.4.1 AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION 97
6.4.2 PERSONALIZED & PRECISION VACCINATION 97
6.4.3 CONNECTED ANIMAL HEALTH ECOSYSTEMS & DIGITAL INTEGRATION 97
6.5 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET 97
6.5.1 INTRODUCTION 97
6.5.2 MARKET POTENTIAL OF AI IN VETERINARY VACCINES 98
6.5.3 AI USE CASES 99
6.5.3.1 Vaccine Discovery and Antigen Identification 99
6.5.3.2 Disease Surveillance and Outbreak Prediction 99
6.5.3.3 Vaccine Formulation and Manufacturing Optimization 99
6.5.3.4 Precision Vaccination and Herd Health Management 99
6.5.3.5 Regulatory Intelligence and Scientific Workflow Automation 99
6.5.4 KEY COMPANIES IMPLEMENTING AI 100
7 SUSTAINABILITY & REGULATORY LANDSCAPE 102
7.1 REGIONAL REGULATIONS & COMPLIANCE 102
7.1.1 REGULATORY ANALYSIS 102
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
7.1.2.1 North America 103
7.1.2.2 Europe 104
7.1.2.3 Rest of the world 105
7.1.3 INDUSTRY STANDARDS 106
7.2 SUSTAINABILITY INITIATIVES 107
7.2.1 RECYCLED & ECO-FRIENDLY MATERIALS FOR VETERINARY VACCINES 107
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 107
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 108
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 109
8.1 KEY STAKEHOLDERS & BUYING CRITERIA 109
8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 109
8.1.2 BUYING CRITERIA 110
8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 111
8.2.1 DECISION-MAKING PROCESS 111
8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
8.2.4 MARKET PROFITABILITY 113
9 VETERINARY VACCINES MARKET, BY TYPE 115
9.1 INTRODUCTION 116
9.2 LIVESTOCK VACCINES 116
9.2.1 BOVINE VACCINES 118
9.2.1.1 Increasing demand for meat and milk to drive market 118
9.2.1.2 Global volume analysis of bovine vaccines, 2024–2031 (thousand units) 120
9.2.2 SMALL RUMINANT VACCINES 120
9.2.2.1 Increased livestock population and favorable government initiatives to propel market growth 120
9.2.2.2 Global volume analysis of small ruminant vaccines, 2024–2031 (thousand units) 123
 
9.3 PORCINE VACCINES 123
9.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH 123
9.3.1.1 Global volume analysis of porcine vaccines, 2024–2031 (thousand units) 126
9.4 POULTRY VACCINES 126
9.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH 126
9.4.1.1 Global volume analysis of poultry vaccines, 2024–2031 (thousand units) 129
9.5 COMPANION ANIMAL VACCINES 129
9.5.1 CANINE VACCINES 131
9.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth 131
9.5.1.2 Global volume analysis of Canine vaccines, 2024–2031(thousand units) 133
9.5.2 FELINE VACCINES 133
9.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth 133
9.5.2.2 Global volume analysis of feline vaccines, 2024–2031 (thousand units) 135
9.6 AQUACULTURE VACCINES 135
9.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH 135
9.6.1.1 Global volume analysis of aquaculture vaccines, 2024–2031 (thousand units) 137
9.7 OTHER VETERINARY VACCINES 137
10 VETERINARY VACCINES MARKET, BY DISEASE 139
10.1 INTRODUCTION 140
10.2 LIVESTOCK DISEASES 140
10.2.1 BOVINE DISEASES 142
10.2.1.1 Increasing government support to aid the market growth 142
10.2.2 SMALL RUMINANT DISEASES 143
10.2.2.1 Growing ruminant vaccines demand to propel the market growth 143
10.3 PORCINE DISEASES 144
10.3.1 PORCINE DISEASES TO ACCOUNT FOR LARGEST SHARE 144
10.4 POULTRY DISEASES 145
10.4.1 GROWING GOVERNMENT PROGRAMME TO CONTROL POULTRY DISEASES 145
10.5 COMPANION ANIMAL DISEASES 147
10.5.1 CANINE DISEASES 148
10.5.1.1 Innovative canine vaccine development to 148
10.5.2 FELINE DISEASES 149
10.5.2.1 Feline disease segment to grow at highest CAGR during forecast period 149
 
10.6 AQUACULTURE DISEASES 150
10.6.1 GROWING FOCUS ON DEVELOPING AQUACULTURE VACCINES 150
10.7 OTHER DISEASES 152
11 VETERINARY VACCINES MARKET, BY TECHNOLOGY 153
11.1 INTRODUCTION 154
11.2 LIVE ATTENUATED VACCINES 154
11.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH 154
11.3 INACTIVATED VACCINES 155
11.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET 155
11.4 TOXOID VACCINES 157
11.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS 157
11.5 RECOMBINANT VACCINES 158
11.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION 158
11.6 OTHER VACCINE TECHNOLOGIES 159
12 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 160
12.1 INTRODUCTION 161
12.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 163
12.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH 163
12.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 165
12.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH 165
12.4 ORAL ROUTE OF ADMINISTRATION 167
12.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH 167
12.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 169
12.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION 169
12.6 INTRAOCULAR ROUTE OF ADMINISTRATION 171
12.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH 171
12.7 OTHER ROUTES OF ADMINISTRATION 173
13 VETERINARY VACCINES MARKET, BY END USER 175
13.1 INTRODUCTION 176
13.2 VETERINARY HOSPITALS 176
13.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET 176
 
13.3 VETERINARY CLINICS 178
13.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH 178
13.4 OTHER END USERS 180
14 VETERINARY VACCINES MARKET, BY REGION 181
14.1 INTRODUCTION 182
14.2 NORTH AMERICA 182
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183
14.2.2 NORTH AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 184
14.2.3 US 188
14.2.3.1 US to dominate North American veterinary vaccines market during forecast period 188
14.2.4 CANADA 192
14.2.4.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines 192
14.3 EUROPE 196
14.3.1 EUROPE: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 197
14.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 201
14.3.3 GERMANY 202
14.3.3.1 Increased poultry consumption and high pet healthcare expenditure to drive market 202
14.3.4 UK 206
14.3.4.1 Rising adoption of pets to augment market growth 206
14.3.5 FRANCE 210
14.3.5.1 Rising companion animal and livestock population to boost market growth 210
14.3.6 ITALY 214
14.3.6.1 Better availability of pet products through large-scale outlets to augment market growth 214
14.3.7 SPAIN 218
14.3.7.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market 218
14.3.8 NETHERLANDS 222
14.3.8.1 High-density livestock production and strong biosecurity standards to drive market growth 222
14.3.9 REST OF EUROPE 227
14.4 ASIA PACIFIC 232
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 232
14.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 233
14.4.3 CHINA 238
14.4.3.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market 238
14.4.4 JAPAN 242
14.4.4.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth 242
14.4.5 INDIA 246
14.4.5.1 Growth in poultry industry and high demand for dairy products to augment market growth 246
14.4.6 AUSTRALIA 250
14.4.6.1 Increase in per capita income and rise in meat consumption to aid market growth 250
14.4.7 SOUTH KOREA 254
14.4.7.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth 254
14.4.8 REST OF ASIA PACIFIC 259
14.5 LATIN AMERICA 263
14.5.1 LATIN AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 264
14.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 268
14.5.3 BRAZIL 269
14.5.3.1 Well-established livestock industry to promote market growth 269
14.5.4 MEXICO 273
14.5.4.1 Focus on pork and poultry meat production to fuel market growth 273
14.5.5 REST OF LATIN AMERICA 277
14.6 MIDDLE EAST & AFRICA 281
14.6.1 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS) 282
14.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 286
14.6.3 GCC COUNTRIES 287
14.6.3.1 Kingdom of Saudi Arabia 291
14.6.3.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth 291
14.6.3.2 UAE 296
14.6.3.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture 296
14.6.3.3 Rest of GCC countries 300
14.6.4 REST OF MIDDLE EAST & AFRICA 305
15 COMPETITIVE LANDSCAPE 310
15.1 INTRODUCTION 310
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024–2026 311
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET 311
15.3 REVENUE ANALYSIS, 2023–2025 313
15.4 MARKET SHARE ANALYSIS, 2025 314
15.4.1 GLOBAL MARKET SHARE ANALYSIS (2025) 314
 
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 316
15.5.1 STARS 316
15.5.2 EMERGING LEADERS 316
15.5.3 PERVASIVE PLAYERS 316
15.5.4 PARTICIPANTS 316
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 318
15.5.5.1 Company footprint 318
15.5.5.2 Type footprint 319
15.5.5.3 Disease footprint 320
15.5.5.4 Technology footprint 321
15.5.5.5 Route of administration footprint 322
15.5.5.6 Region footprint 323
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 324
15.6.1 PROGRESSIVE COMPANIES 324
15.6.2 RESPONSIVE COMPANIES 324
15.6.3 DYNAMIC COMPANIES 324
15.6.4 STARTING BLOCKS 324
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 326
15.6.5.1 Detailed list of key startups/SMEs 326
15.6.5.2 Competitive benchmarking of key startups/SMEs 327
15.7 COMPANY VALUATION & FINANCIAL METRICS 328
15.7.1 FINANCIAL METRICS 328
15.7.2 COMPANY VALUATION 328
15.8 BRAND/PRODUCT COMPARISON 329
15.9 COMPETITIVE SCENARIO 330
15.9.1 PRODUCT LAUNCHES & APPROVALS 330
15.9.2 DEALS 331
15.9.3 EXPANSIONS 331
15.9.4 OTHER DEVELOPMENTS 332
16 COMPANY PROFILES 333
16.1 KEY PLAYERS 333
16.1.1 MERCK & CO., INC. 333
16.1.1.1 Business overview 333
16.1.1.2 Products offered 335
16.1.1.3 Recent developments 338
16.1.1.3.1 Product launches & approvals 338
16.1.1.3.2 Deals 339
16.1.1.3.3 Expansions 339
16.1.1.4 MnM view 339
16.1.1.4.1 Right to win 339
16.1.1.4.2 Strategic choices 339
16.1.1.4.3 Weaknesses & competitive threats 339
16.1.2 ZOETIS SERVICES LLC 340
16.1.2.1 Business overview 340
16.1.2.2 Products offered 341
16.1.2.3 Recent developments 343
16.1.2.3.1 Product approvals 343
16.1.2.3.2 Deals 343
16.1.2.3.3 Expansions 343
16.1.2.3.4 Other developments 344
16.1.2.4 MnM view 344
16.1.2.4.1 Right to win 344
16.1.2.4.2 Strategic choices 344
16.1.2.4.3 Weaknesses & competitive threats 344
16.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 345
16.1.3.1 Business overview 345
16.1.3.2 Products offered 346
16.1.3.3 Recent developments 347
16.1.3.3.1 Product launches 347
16.1.3.3.2 Expansions 348
16.1.3.4 MnM view 348
16.1.3.4.1 Right to win 348
16.1.3.4.2 Strategic choices 348
16.1.3.4.3 Weaknesses & competitive threats 348
16.1.4 ELANCO 349
16.1.4.1 Business overview 349
16.1.4.2 Products offered 350
16.1.4.3 Recent developments 352
16.1.4.3.1 Product approvals 352
16.1.4.3.2 Deals 352
16.1.4.4 MnM view 353
16.1.4.4.1 Right to win 353
16.1.4.4.2 Strategic choices 353
16.1.4.4.3 Weaknesses & competitive threats 353
16.1.5 VIRBAC 354
16.1.5.1 Business overview 354
16.1.5.2 Products offered 356
16.1.5.3 Recent developments 357
16.1.5.3.1 Product launches 357
16.1.5.3.2 Deals 358
16.1.5.3.3 Expansions 358
16.1.5.4 MnM view 359
16.1.5.4.1 Right to win 359
16.1.5.4.2 Strategic choices 359
16.1.5.4.3 Weaknesses & competitive threats 359
16.1.6 CEVA 360
16.1.6.1 Business overview 360
16.1.6.2 Products offered 360
16.1.6.3 Recent developments 362
16.1.6.3.1 Product launches 362
16.1.6.3.2 Expansions 362
16.1.7 PHIBRO ANIMAL HEALTH CORPORATION 363
16.1.7.1 Business overview 363
16.1.7.2 Products offered 364
16.1.8 HESTER BIOSCIENCES LIMITED 366
16.1.8.1 Business overview 366
16.1.8.2 Products offered 367
16.1.8.3 Recent developments 369
16.1.8.3.1 Product approvals 369
16.1.8.3.2 Deals 369
16.1.9 NEOGEN CORPORATION 370
16.1.9.1 Business overview 370
16.1.9.2 Products offered 371
16.1.9.3 Recent developments 372
16.1.9.3.1 Deals 372
16.1.10 HIPRA 373
16.1.10.1 Business overview 373
16.1.10.2 Products offered 373
16.1.10.3 Recent developments 375
16.1.10.3.1 Product launches 375
16.1.10.3.2 Deals 376
16.1.11 BIOGÉNESIS BAGÓ 377
16.1.11.1 Business overview 377
16.1.11.2 Products offered 377
16.1.11.3 Recent developments 378
16.1.11.3.1 Deals 378
16.1.11.3.2 Expansions 378
16.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 379
16.1.12.1 Business overview 379
16.1.12.2 Products offered 380
16.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. 382
16.1.13.1 Business overview 382
16.1.13.2 Products offered 382
16.1.13.2.1 Other developments 384
 
16.1.14 JINYU BIOTECHNOLOGY CO., LTD. 385
16.1.14.1 Business overview 385
16.1.14.2 Products offered 385
16.1.14.3 Recent developments 387
16.1.14.3.1 Product approvals 387
16.1.15 VAXXINOVA INTERNATIONAL B.V. 388
16.1.15.1 Business overview 388
16.1.15.2 Products offered 388
16.1.15.3 Recent developments 390
16.1.15.3.1 Product approvals 390
16.1.15.3.2 Deals 390
16.1.15.3.3 Expansions 391
16.2 OTHER COMPANIES 392
16.2.1 ENDOVAC ANIMAL HEALTH REBRAND CA 392
16.2.2 BRILLIANT BIO PHARMA PRIVATE LIMITED 393
16.2.3 APTIMMUNE 394
16.2.4 INDIAN IMMUNOLOGICALS LTD. 395
16.2.5 TORIGEN 396
16.2.6 INTAS PHARMACEUTICALS LTD. 396
16.2.7 OUROFINO S.A 397
16.2.8 BIOVAC LTD. 398
16.2.9 LABORATOIRE LCV 399
16.2.10 KYORITSU SEIYAKU CORPORATION 400
17 RESEARCH METHODOLOGY 401
17.1 RESEARCH DATA 401
17.1.1 SECONDARY DATA 401
17.1.1.1 Key data from secondary sources 403
17.1.2 PRIMARY DATA 404
17.1.2.1 Key data from primary sources 405
17.1.2.2 Key industry insights 405
17.1.2.3 Breakdown of primary interviews 406
17.1.2.4 Key industry insights 407
17.2 MARKET SIZE ESTIMATION 407
17.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 408
17.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 410
17.2.3 APPROACH 3: BOTTOM APPROACH 411
17.2.4 APPROACH 4: TOP-DOWN 411
17.2.5 BASE NUMBER CALCULATION 412
17.2.6 COMPANY PRESENTATIONS 412
17.2.7 PRIMARY INTERVIEWS 412
17.2.8 APPROACH 5: VOLUME ESTIMATION 412
17.2.9 APPROACH 6: DEMAND-SIDE 412
17.3 MARKET BREAKDOWN AND DATA TRIANGULATION 417
17.4 MARKET SHARE ASSESSMENT 418
17.5 RESEARCH ASSUMPTIONS 418
17.5.1 STUDY ASSUMPTIONS 418
17.5.2 GROWTH RATE ASSUMPTIONS 418
17.6 RISK ASSESSMENT 419
17.6.1 RESEARCH LIMITATIONS 419
18 APPENDIX 420
18.1 DISCUSSION GUIDE 420
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 426
18.3 CUSTOMIZATION OPTIONS 428
18.4 RELATED REPORTS 428
18.5 AUTHOR DETAILS 429

ページTOPに戻る

List of Tables/Graphs

TABLE 1 STANDARD CURRENCY CONVERSION RATES 38
TABLE 2 GLOBAL MEAT MARKET INDICATORS, 2024 VS. 2025 52
TABLE 3 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK (DEVELOPED VS. EMERGING MARKETS) 53
TABLE 4 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 53
TABLE 5 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 54
TABLE 6 KEY COST AND OPERATIONAL CHALLENGES ASSOCIATED WITH VACCINE DEVELOPMENT 55
TABLE 7 VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 63
TABLE 8 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 66
TABLE 9 LIST OF KEY VETERINARY VACCINE MANUFACTURERS 71
TABLE 10 LIST OF KEY END USERS 72
TABLE 11 LIST OF KEY REGULATORY BODIES 73
TABLE 12 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025 (USD) 74
TABLE 13 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025 (USD) 75
TABLE 14 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER,
2023–2025 (USD) 76
TABLE 15 AVERAGE SELLING PRICE TREND OF CANINE VACCINES, BY REGION,
2023–2025 (USD) 77
TABLE 16 IMPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD THOUSAND) 78
TABLE 17 EXPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY,
2021–2025 (USD THOUSAND) 78
TABLE 18 VETERINARY VACCINES MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027 80
TABLE 19 BOVILIS NASALGEN-C: IMPROVED GROWTH PERFORMANCE AND REDUCED RESPIRATORY DISEASE IN VEAL CALVES 82
TABLE 20 UNISTRAIN PRRS: ENHANCED PRRS CONTROL AND REDUCED ANTIBIOTIC USAGE IN COMMERCIAL SWINE PRODUCTION 83
TABLE 21 FAO RABIES VACCINATION CASE STUDY 83
TABLE 22 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2025 84
TABLE 23 KEY PRODUCT-RELATED TARIFF 85
TABLE 24 NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA 86
TABLE 25 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 86
TABLE 26 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 87
TABLE 27 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 87
TABLE 28 VETERINARY VACCINES MARKET: KEY PATENTS, 2023–2025 94
TABLE 29 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 30 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104
TABLE 31 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES 110
TABLE 33 KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER 111
TABLE 34 VETERINARY VACCINES MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES 112
TABLE 35 VETERINARY VACCINES MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
TABLE 36 VETERINARY VACCINES MARKET: KEY PROFITABILITY DRIVERS 114
TABLE 37 VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 116
TABLE 38 LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 116
TABLE 39 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 117
TABLE 40 KEY PLAYERS PROVIDING BOVINE VACCINES 118
TABLE 41 BOVINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 42 BOVINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 120
TABLE 43 KEY PLAYERS PROVIDING SMALL RUMINANT VACCINES 121
TABLE 44 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 45 SMALL RUMINANT VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 123
TABLE 46 KEY PLAYERS PROVIDING PORCINE VACCINES 124
TABLE 47 PORCINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 48 PORCINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 126
TABLE 49 KEY PLAYERS PROVIDING POULTRY VACCINES 127
TABLE 50 POULTRY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 51 POULTRY VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 129
TABLE 52 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 129
TABLE 53 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 54 KEY PLAYERS PROVIDING CANINE VACCINES 131
TABLE 55 CANINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 56 CANINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 133
TABLE 57 KEY PLAYERS PROVIDING FELINE VACCINES 134
TABLE 58 FELINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 59 FELINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 135
TABLE 60 KEY PLAYERS PROVIDING AQUACULTURE VACCINES 136
TABLE 61 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 62 AQUACULTURE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 137
TABLE 63 KEY PLAYERS PROVIDING OTHER COMMERCIAL VETERINARY VACCINES 137
TABLE 64 OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 65 VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 140
TABLE 66 LIVESTOCK VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 140
TABLE 67 LIVESTOCK DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 68 BOVINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 69 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 70 PORCINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 71 POULTRY DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 72 COMPANION ANIMAL VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 147
TABLE 73 COMPANION ANIMAL DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 74 CANINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 75 FELINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 76 AQUACULTURE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 77 OTHER DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 78 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 154
TABLE 79 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 80 INACTIVATED VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 81 TOXOID VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 82 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 83 OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 84 ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER 161
TABLE 85 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 163
TABLE 86 COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION 163
TABLE 87 VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 88 COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR ROUTE OF ADMINISTRATION 165
TABLE 89 VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 90 COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION 167
TABLE 91 VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 92 COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY ROUTE OF ADMINISTRATION 169
TABLE 93 VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 94 COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR ROUTE OF ADMINISTRATION 171
TABLE 95 VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 96 COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION 173
TABLE 97 VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 98 VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 176
TABLE 99 VETERINARY HOSPITALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 100 VETERINARY CLINICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 101 OTHER END USERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 102 VETERINARY VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 103 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 184
TABLE 104 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 105 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 106 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 107 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 108 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 186
TABLE 109 NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 110 NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 111 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 187
TABLE 112 NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 188
TABLE 113 NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 188
TABLE 114 US: KEY MACROINDICATORS 189
TABLE 115 US: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 116 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 117 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 118 US: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 190
TABLE 119 US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 120 US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 121 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 191
TABLE 122 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 192
TABLE 123 US: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 192
TABLE 124 CANADA: KEY MACROINDICATORS 193
TABLE 125 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 126 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 127 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 128 CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 194
TABLE 129 CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 130 CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 131 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 195
TABLE 132 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 196
TABLE 133 CANADA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 196
TABLE 134 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 197
TABLE 135 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 136 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 137 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 138 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 139 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 199
TABLE 140 EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 141 EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 142 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 200
TABLE 143 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 201
TABLE 144 EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 201
TABLE 145 GERMANY: KEY MACROINDICATORS 202
TABLE 146 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 147 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 148 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 149 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 204
TABLE 150 GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 151 GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 152 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 205
TABLE 153 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 206
TABLE 154 GERMANY: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 206
TABLE 155 UK: KEY MACROINDICATORS 207
TABLE 156 UK: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 157 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207
TABLE 158 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 159 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 208
TABLE 160 UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 161 UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 162 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209
TABLE 163 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 210
TABLE 164 UK: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 210
TABLE 165 FRANCE: KEY MACROINDICATORS 211
TABLE 166 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 167 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 168 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212
TABLE 169 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 212
TABLE 170 FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 171 FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 172 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 213
TABLE 173 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 214
TABLE 174 FRANCE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 214
TABLE 175 ITALY: KEY MACROINDICATORS 215
TABLE 176 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 177 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 178 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 179 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 216
TABLE 180 ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 181 ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 182 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 217
TABLE 183 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 218
TABLE 184 ITALY: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 218
TABLE 185 SPAIN: KEY MACROINDICATORS 219
TABLE 186 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 187 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220
TABLE 188 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 220
TABLE 189 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 220
TABLE 190 SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 191 SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 192 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 221
TABLE 193 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 222
TABLE 194 SPAIN: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 222
TABLE 195 NETHERLANDS: KEY MACROINDICATORS 223
TABLE 196 NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 197 NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 198 NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 199 NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 224
TABLE 200 NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 201 NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 202 NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 226
TABLE 203 NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 226
TABLE 204 NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 227
TABLE 205 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 206 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 207 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 208 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 229
TABLE 209 REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 210 REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 211 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 230
TABLE 212 REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 231
TABLE 213 REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 231
TABLE 214 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 233
TABLE 215 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 216 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 217 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 218 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 219 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 235
TABLE 220 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 221 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 222 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 237
TABLE 223 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 237
TABLE 224 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 238
TABLE 225 CHINA: KEY MACROINDICATORS 238
TABLE 226 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 227 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 228 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 229 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 240
TABLE 230 CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 231 CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 232 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 241
TABLE 233 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 242
TABLE 234 CHINA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 242
TABLE 235 JAPAN: KEY MACROINDICATORS 243
TABLE 236 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 237 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 238 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 239 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 244
TABLE 240 JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 241 JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 242 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245
TABLE 243 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 246
TABLE 244 JAPAN: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 246
TABLE 245 INDIA: KEY MACROINDICATORS 247
TABLE 246 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 247 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 248 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 249 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 248
TABLE 250 INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 251 INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 252 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 249
TABLE 253 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 250
TABLE 254 INDIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 250
TABLE 255 AUSTRALIA: KEY MACROINDICATORS 251
TABLE 256 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 257 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 258 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 259 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 252
TABLE 260 AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 261 AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 262 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 253
TABLE 263 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 254
TABLE 264 AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 254
TABLE 265 SOUTH KOREA: KEY MACROINDICATORS 255
TABLE 266 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 267 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 268 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 269 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 257
TABLE 270 SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 257
TABLE 271 SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 272 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 258
TABLE 273 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 259
TABLE 274 SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 259
TABLE 275 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 276 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 277 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 278 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 261
TABLE 279 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 280 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 281 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 262
TABLE 282 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 263
TABLE 283 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 263
TABLE 284 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 264
TABLE 285 LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 286 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 287 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 288 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 289 LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 266
TABLE 290 LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 291 LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 292 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267
TABLE 293 LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 268
TABLE 294 LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 268
TABLE 295 BRAZIL: KEY MACROINDICATORS 269
TABLE 296 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 297 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 298 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 270
TABLE 299 BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 271
TABLE 300 BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 301 BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 302 BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 272
TABLE 303 BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 273
TABLE 304 BRAZIL: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 273
TABLE 305 MEXICO: KEY MACROINDICATORS 274
TABLE 306 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 307 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 308 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 309 MEXICO: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 275
TABLE 310 MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 311 MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 312 MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276
TABLE 313 MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 277
TABLE 314 MEXICO: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 277
TABLE 315 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 316 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 317 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 318 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 279
TABLE 319 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 320 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 321 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280
TABLE 322 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 281
TABLE 323 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 281
TABLE 324 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS) 282
TABLE 325 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 326 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 327 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 328 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 329 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 284
TABLE 330 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 331 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 285
TABLE 332 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 285
TABLE 333 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 286
TABLE 334 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 286
TABLE 335 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 287
TABLE 336 GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 337 GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 338 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 289
TABLE 339 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 340 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 341 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 290
TABLE 342 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 291
TABLE 343 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 291
TABLE 344 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 292
TABLE 345 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 346 KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 347 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 348 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION) 294
TABLE 349 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 350 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 351 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 295
TABLE 352 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 296
TABLE 353 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION) 296
TABLE 354 UNITED ARAB EMIRATES: KEY MACROINDICATORS 297
TABLE 355 UAE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 356 UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 357 UAE: COMPANION ANIMAL VACCINES M